title: Randomized controlled trial of oral antifungal treatment for severe asthma with fungal sensitization: The Fungal Asthma Sensitization Trial (FAST) study.
abstract: BACKGROUND
  Some patients with severe asthma are immunologically sensitized to one or more fungi, a clinical entity categorized as severe asthma with fungal sensitization (SAFS). It is not known whether SAFS responds to antifungal therapy.
  
  
  OBJECTIVE
  To evaluate the response of SAFS to oral itraconazole.
  
  
  METHODS
  Patients with severe asthma sensitized to at least one of seven fungi by skin prick or specific IgE testing were recruited. All had total IgE less than 1,000 IU/ml and negative Aspergillus precipitins. They were treated with oral itraconazole (200 mg twice daily) or placebo for 32 weeks, with follow-up for 16 weeks.
  
  
  RESULTS
  The primary end point was change in the Asthma Quality of Life Questionnaire (AQLQ) score, with rhinitis score, total IgE, and respiratory function as secondary end points. Fifty-eight patients were enrolled, of whom 41% had been hospitalized in the previous year. Baseline mean AQLQ score was 4.13 (range, 1-7). At 32 weeks, the improvement (95% confidence interval) in AQLQ score was +0.85 (0.28, 1.41) in the antifungal group, compared with a -0.01 (-0.43, 0.42) change in the placebo group (P = 0.014). Rhinitis score improved (-0.43) in the antifungal, and deteriorated (+0.17) in the placebo group (P = 0.013). Morning peak flow improved (20.8 L/minute, P = 0.028) in the antifungal group. Total serum IgE decreased in the antifungal group (-51 IU/ml) but increased in placebo group (+30 IU/ml) (P = 0.001). No severe adverse events were observed, but seven patients developed adverse events requiring discontinuation, five in the antifungal group.
  
  
  CONCLUSIONS
  SAFS responds to oral antifungal therapy as judged by large improvements in quality of life in about 60% of patients.
authors.affiliation: School of Translational Medicine, University of Manchester, Manchester, UK. ddenning@manchester.ac.uk
authors.forename: David W
authors.initials: DW
authors.lastname: Denning
authors.forename: B Ronan
authors.initials: BR
authors.lastname: O'Driscoll
authors.forename: Georgina
authors.initials: G
authors.lastname: Powell
authors.forename: Fiona
authors.initials: F
authors.lastname: Chew
authors.forename: Graham T
authors.initials: GT
authors.lastname: Atherton
authors.forename: Aashish
authors.initials: A
authors.lastname: Vyas
authors.forename: John
authors.initials: J
authors.lastname: Miles
authors.forename: Julie
authors.initials: J
authors.lastname: Morris
authors.forename: Robert M
authors.initials: RM
authors.lastname: Niven
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000935:Antifungal Agents / Q000097:blood / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy* / Q000382:microbiology* / Q000503:physiopathology; D005260:Female; D006801:Humans; D017964:Itraconazole / Q000097:blood / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011788:Quality of Life; D012129:Respiratory Function Tests; D011795:Surveys and Questionnaires; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000935:Antifungal Agents; D017964:Itraconazole